{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:22:01Z","timestamp":1790508121725,"version":"4.1.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016056"],"award-info":[{"award-number":["P30CA016056"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006398","name":"Roswell Park Alliance Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006398","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001767","name":"National Foundation for Cancer Research","doi-asserted-by":"publisher","award":["P30CA016056"],"award-info":[{"award-number":["P30CA016056"]}],"id":[{"id":"10.13039\/100001767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ijrobp.2026.03.003","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T17:02:19Z","timestamp":1773421339000},"page":"142-146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-Term Analysis of One Versus Three Fractions of Stereotactic Body Radiation Therapy for Peripheral Stage I to II Non-Small Cell Lung Cancer: A Randomized, Multi-Institution, Phase 2 Trial"],"prefix":"10.1016","volume":"126","author":[{"given":"Anurag K.","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0261-0334","authenticated-orcid":false,"given":"Mark K.","family":"Farrugia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Stephans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Bogart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne","family":"Groman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory M.","family":"Videtic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2026.03.003_bib0001","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5306\/wjco.v10.i1.14","article-title":"Stereotactic body radiation therapy for non-small cell lung cancer: a review","volume":"10","author":"Prezzano","year":"2019","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.003_bib0002","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines: Non-small cell lung cancer. Version 5. March 13, 2026."},{"key":"10.1016\/j.ijrobp.2026.03.003_bib0003","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.ijrobp.2019.08.019","article-title":"One versus three fractions of stereotactic body radiation therapy for peripheral stage I to II non-small cell lung cancer: a randomized, multi-institution, phase 2 trial","volume":"105","author":"Singh","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.03.003_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109976","article-title":"What is the predictive value of RECIST criteria following stereotactic lung radiation?","volume":"190","author":"Gulstene","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.003_bib0005","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/j.prro.2017.10.008","article-title":"Optimal imaging surveillance after stereotactic ablative radiation therapy for early-stage non-small cell lung cancer: findings of an International Delphi Consensus Study","volume":"8","author":"Nguyen","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.003_bib0006","doi-asserted-by":"crossref","first-page":"790","DOI":"10.3390\/cancers14030790","article-title":"Systematic review of single-fraction stereotactic body radiation therapy for early stage non-small-cell lung cancer and lung oligometastases: how to stop worrying and love one and done","volume":"14","author":"Bartl","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijrobp.2026.03.003_bib0007","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.ijrobp.2018.11.051","article-title":"Long-term follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): a randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer","volume":"103","author":"Videtic","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.03.003_bib0008","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cllc.2019.07.007","article-title":"Improved overall survival with comprehensive local consolidative therapy in synchronous oligometastatic non-small-cell lung cancer","volume":"21","author":"Mitchell","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ijrobp.2026.03.003_bib0009","doi-asserted-by":"crossref","unstructured":"Moghanaki D, Videtic GM, Singh AK, et al. Fifteen-year trends in single-fraction SBRT utilization for stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2025;123(1)(suppl):e193.","DOI":"10.1016\/j.ijrobp.2025.06.3719"},{"key":"10.1016\/j.ijrobp.2026.03.003_bib0010","doi-asserted-by":"crossref","DOI":"10.1200\/OP-25-00826","article-title":"Fifteen-year national trends in single-fraction stereotactic body radiation therapy utilization for stage I non-small cell lung cancer","author":"Moghanaki","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.ijrobp.2026.03.003_bib0011","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.ijrobp.2025.04.022","article-title":"International patterns of practice for SABR for early-stage non-small cell lung cancer: are we all in sync?","volume":"123","author":"Alfaifi","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.03.003_bib0012","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.ijrobp.2024.06.033","article-title":"Ablative Radiation Therapy to Restrain Everything Safely Treatable (ARREST): a phase 1 study of stereotactic ablative radiation therapy for polymetastatic disease","volume":"120","author":"Nguyen","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.03.003_bib0013","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1186\/s12885-019-5977-6","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial","volume":"19","author":"Palma","year":"2019","journal-title":"BMC Cancer"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626004876?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626004876?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T07:35:58Z","timestamp":1786520158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301626004876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0360301626004876"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.03.003","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Analysis of One Versus Three Fractions of Stereotactic Body Radiation Therapy for Peripheral Stage I to II Non-Small Cell Lung Cancer: A Randomized, Multi-Institution, Phase 2 Trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}